Hsa_circ_0005576 promotes the osimertinib resistance through miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer science"
DOI: 10.1111/cas.15177
Abstract: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung adenocarcinoma (LUAD) harboring activating mutations, but patients ultimately develop acquired resistance. Circular RNAs are involved in EGFR-TKI resistance, while the role… read more here.
Keywords: luad; mir 512; osimertinib resistance; hsa circ ... See more keywords